ABSTRACT
BACKGROUND AND OBJECTIVES: Benign Prostatic Hyperplasia (BPH) is a common urological disorder as men get older. BPH can cause uncomfortable urinary tract symptoms. Given the high incidence of the disease, further research is an undeniable necessity for its better management. In this research, the efficacy of Urtica Dioica root extract (UDE) on clinical and biochemical parameters were evaluated in this type of patients. MATERIALS AND METHODS: Participants were 60 men with BPH that randomly allocated to two equal groups (Intervention = 30 and Comparison = 30). Block balanced Randomization method was performed using a computer by a trained nurse. Intervention and comparison groups received 450 mg day-1 UDE and placebo as tablets for 12 weeks, respectively. The main outcome was changes in International Prostate Symptoms Score (IPSS) from baseline to end of treatment. Data were collected by completing a standard questionnaire and performing relevant tests based on common laboratory methods. RESULTS: UDE had an intermediate effect on IPSS, a small effect on serum high-sensitivity C-reactive protein (hs-CRP), intermediate to large effect on malondialdehyde (MDA) levels and intermediate effect on superoxide dismutase (SOD) activity. The magnitude of the effects of UDE on other parameters was overall negligible compared to the comparison and not significant. No side effects were seen in these patients following tablet usage. CONCLUSION: UDE consumption for 12 weeks among BPH patients had clinically significant effects on IPSS, serum hs-CRP, MDA and SOD activity.
Subject(s)
Plant Extracts/therapeutic use , Plant Roots/metabolism , Prostatic Hyperplasia/drug therapy , Urtica dioica/metabolism , Aged , Aged, 80 and over , C-Reactive Protein/metabolism , Double-Blind Method , Humans , Iran , Male , Malondialdehyde/metabolism , Middle Aged , Oxidative Stress , Placebos , Superoxide Dismutase/metabolism , Surveys and Questionnaires , Symptom Assessment , TabletsABSTRACT
Vanadyl sulfate (VS) is an ingredient in some food supplements and experimental drugs. This study was designed to assay the effects of VS on biomarkers of oxidative stress and inflammation in renal tissue of rats with diabetes type 2. 30 male Wistar rats were divided into three equal groups as follow: non-diabetics, non-treated diabetics and VS-treated diabetics. Diabetes type 2 has been induced through high fat diet and fructose in the animals. Diabetic rats were treated with 25 mg/kgBW of VS in water for 12 weeks. At the end of study, glucose and insulin were measured using commercially available kits in serum and biomarkers of oxidative stress and inflammation in renal homogenates of animals were measured by related methods. Compared to controls, glucose and insulin were increased significantly in non-treated diabetic rats (p-value <0.05) that showed the induction of diabetes type 2 in rats. The results showed that in VS-treated diabetic rats compared to the non-treated diabetic group, vanadyl sulfate significantly reduced the glucose and insulin secretion and changed renal inflammatory and oxidative markers, except protein carbonyl so that we couldn't find any significant changes. Our study showed that vanadyl supplementation had positive effects on oxidative stress and inflammation biomarkers in kidney of diabetic rats
Subject(s)
Animals , Male , Rats , Sulfates/analysis , Vanadates/analysis , Biomarkers/analysis , Pharmaceutical Preparations/administration & dosage , Interleukin-1/antagonists & inhibitors , Interleukin-10/antagonists & inhibitors , Oxidative Stress/immunology , Dietary Supplements/adverse effects , Diabetes Mellitus, Type 2/pathology , Insulin Secretion , Insulin/pharmacologyABSTRACT
BACKGROUND AND OBJECTIVE: Hypertension is a long-term medical condition in which the blood pressure is gradually elevated. In this project, the effects of olive leaf extract (OLE) were evaluated on metabolic response, liver and kidney functions and also biomarkers of inflammation in hypertensive patients. MATERIALS AND METHODS: In this randomized double-blind placebo controlled clinical trial, 60 hypertensive patients, aged 30-60 years old had participated. Patients were randomly assigned into two groups to receive either OLE or placebo tablets for 12 weeks. At the beginning and end of the intervention, metabolic parameters and biomarkers of liver, kidney and inflammation were measured in sera of the participants using available laboratory methods. RESULTS: Compared with the placebo, changes in parameters associated with glucose metabolism were not statistically significant (p>0.05). The OLE tablets did not have significant effect on liver enzymes, total protein, albumin, urea and creatinine (p>0.05), but significantly decreased interleukin-6, interleukin-8 and tumor necrosis factor alpha as inflammatory biomarkers (p<0.05) in OLE group compared to the placebo group. CONCLUSION: The results concluded that inflammation as a major cause of hypertension was significantly decreased in patients using OLE tablets.
